

23. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. *J Clin Invest* 1988; **82**:322-330.
24. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin-converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. *J Clin Invest* 1990; **85**:541-549.
25. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. *J Clin Invest* 1986; **77**:1925-1930.
26. Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. *Diabetologia* 1989; **32**:326-328.
27. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long-term effects of antihypertensive therapy in the diabetic rat. *Kidney Int* 1989; **36**:526-536.
28. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. *N Engl J Med* 1989; **313**:1617-1620.
29. Hommel E, Parving HH, Mathiesen E, Edsberg B, Nielson MD, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. *Br Med J* 1986; **293**:467-470.
30. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. *Br Med J* 1986; **293**:471-474.
31. Marre M, Leblanc H, Suarez L, Guyenne T-T, Menard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. *Br Med J* 1987; **294**:1444-1452.
32. Stornello M, Valvo EV, Puglia N, Scapellato L. Angiotensin-converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria. *J Hypertens* 1988; **6**(suppl 4):S464-S466.
33. Valvo E, Bedogna V, Casagrande P, et al. Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alteration. *Am J Med* 1988; **85**:344-348.
34. Parving H-H, Hommel E, Nielson MD, Grese J. Effect of captopril on blood pressure and kidney function in normotensive insulin-independent diabetes with nephropathy. *Br Med J* 1989; **299**:533-536.
35. Mimran A, Insura A, Ribstein J, Monnier L, Bringer J, Mirouze J. Contrasting effects of captopril and rifedipine in normotensive patients with incipient diabetic nephropathy. *J Hypertens* 1988; **6**:919-923.
36. Marre M, Chatellier G, Leblanc H, Guyene T-T, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetes with microalbuminuria. *Br Med J* 1988; **297**:1092-1095.
37. Morelli E, Loon N, Meyer T, Peters W, Meyers BD. Effects of converting enzyme inhibition as barrier function in diabetic glomerulopathy. *Diabetes* 1990; **39**:76-82.
38. Brouhard BH, Cunningham RJ. Five-year follow-up of angiotensin-converting enzyme inhibitors for diabetic nephropathy. *Diabetes* 1990; **39**(Suppl 1):197A.
39. Trachtman H, Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. *J Pediatr* 1988; **112**:295-298.
40. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L. Converting enzyme inhibition in chronic renal failure. *Am J Kidney Dis* 1989; **13**:120-126.
41. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Reduction of proteinuria by angiotensin-converting enzyme inhibition. *Kidney Int* 1987; **32**:78-83.
42. Ruilope LM, Miranda B, Oliet A, et al. Control of hypertension with the angiotensin-converting enzyme inhibitor captopril reduces glomerular proteinuria. *J Hypertens* 1988; **6**(Suppl 4):S467-S469.
43. Fitzwater DS, Brouhard BH, Cunningham RJ. Use of angiotensin-converting enzyme inhibitors for the treatment of focal segmental glomerulosclerosis. *Am J Dis Child* 1990; **144**:527.

Errata

Two errors occurred in the article, "Management of inflammatory bowel disease: 30 years of observation," by Michener and associates (*Cleve Clin J Med* 1990; **57**:685-691). In Table 2, p 686, the entry "Duration of symptoms to diagnosis" should be expressed in months.

The last sentence on p 689 should read, "The occurrence of only one colon cancer among patients with ulcerative colitis in the 1975-1984 review period should reassure those with concerns about an association between the two diseases."